Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Amgen Inc., consolidated income statement

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Product sales	32,026)	26,910)	24,801)	24,297)	24,240)
Cost of sales	(12,858)	(8,451)	(6,406)	(6,454)	(6,159)
Gross profit from product sales	19,168)	18,459)	18,395)	17,843)	18,081)
Other revenues	1,398)	1,280)	1,522)	1,682)	1,184)
Research and development	(5,964)	(4,784)	(4,434)	(4,819)	(4,207)
Acquired in-process research and development	—)	—)	—)	(1,505)	—)
Selling, general and administrative	(7,096)	(6,179)	(5,414)	(5,368)	(5,730)
Other	(248)	(879)	(503)	(194)	(189)
Operating income	7,258)	7,897)	9,566)	7,639)	9,139)
Interest expense, net	(3,155)	(2,875)	(1,406)	(1,197)	(1,262)
Other income (expense), net	506)	2,833)	(814)	259)	256)
Income before income taxes	4,609)	7,855)	7,346)	6,701)	8,133)
Provision for income taxes	(519)	(1,138)	(794)	(808)	(869)
Net income	4,090)	6,717)	6,552)	5,893)	7,264)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Income statement item	Description	The company
Product sales	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	Amgen Inc. product sales increased from 2022 to 2023 and from 2023 to 2024.
Operating income	The net result for the period of deducting operating expenses from operating revenues.	Amgen Inc. operating income decreased from 2022 to 2023 and from 2023 to 2024.
Income before income taxes	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Amgen Inc. income before income taxes increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Net income	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Amgen Inc. net income increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.

Amgen Inc. (NASDAQ:AMGN)

Income Statement